Approval of teplizumab: implications for patients

Type 1 diabetes mellitus (T1DM) can be predicted, and immune therapy can alter the progression of the disease. The FDA's approval of teplizumab as the first disease-modifying therapy for T1DM and the first therapy aimed at delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.

Automated summary

Type 1 diabetes mellitus (T1DM) can be predicted and altered by immune therapy. The FDA's approval of teplizumab as the first disease-modifying therapy for T1DM and delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.